Expert Consensus on Intelligent Clinical Research


In recent years, developments in the internet and artificial intelligence have driven innovation in clinical research models. Adopting digital and intelligent research approaches can, to some extent, reduce travel burden and time costs for trial participants and improve participant compliance. Direct data capture and transmission help ensure the timeliness and authenticity of records as well as study quality, reduce documentation workload for research staff, and decrease data transcription errors, while also helping shorten drug development timelines and lower study costs. Since the COVID-19 pandemic in particular, remote and intelligent solutions have sparked reflection and discussion across the entire industry.
To promote the application of intelligent clinical research in China and provide a reference basis for its implementation and quality oversight, Dr. Qin Long, General Manager of EClinCloud, served as an expert panel member in joint discussions with specialists from drug regulatory authorities, industry associations, research institutions, sponsors, and contract research organizations (CROs). In June 2020, the panel officially published the "Expert Consensus on Intelligent Clinical Research" in the Chinese Journal of New Drugs and Clinical Remedies as a reference for the clinical research industry.


